SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    P Zhang, K Gao, X Jin, J Ma, J Peng, R Wumaier, Y Tang, Y Zhang, J An, Q Yan, Y Dong, H Huang, L Yu, C Wang, Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover, Cell Death and Disease, 2015, 6, 3, e1687

    CrossRef

  2. 2
    Emily A. Stevens, Cristina P. Rodriguez, Genomic medicine and targeted therapy for solid tumors, Journal of Surgical Oncology, 2015, 111, 1
  3. 3
    Yingying Qian, Dongmin Shi, Jinrong Qiu, Fang Zhu, Jing Qian, Shaohua He, Yongqian Shu, Yongmei Yin, Xiaofeng Chen, ObRb downregulation increases breast cancer cell sensitivity to tamoxifen, Tumor Biology, 2015,

    CrossRef

  4. 4
    Lakshmy Nair, Ana Maria Gonzalez-Angulo, Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies, 2015,

    CrossRef

  5. 5
    Elsa Dalmau, Alejandra Armengol-Alonso, Montserrat Muñoz, Miguel Ángel Seguí-Palmer, Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer, The Breast, 2014, 23, 6, 710

    CrossRef

  6. 6
    Stefan Glück, Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor–Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action, Clinical Breast Cancer, 2014, 14, 2, 75

    CrossRef

  7. 7
    Ingrid A Mayer, What is the potential of using PI3K inhibitors in the management of breast cancer in the clinic?, Breast Cancer Management, 2014, 3, 4, 345

    CrossRef

  8. 8
    Richard J. Santen, Linda R. Duska, Stephen H. Culp, Yen & Jaffe's Reproductive Endocrinology, 2014,

    CrossRef

  9. 9
    Jean-Claude Lapraz, Kamyar M Hedayat, Patrice Pauly, Endobiogeny: A Global Approach to Systems Biology (Part 2 of 2), Global Advances in Health and Medicine, 2013, 2, 2, 32

    CrossRef

  10. 10
    Marcelo Madeira, André Mattar, Ângela Logullo, Fernando Soares, Luiz Gebrim, Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer, BMC Cancer, 2013, 13, 1, 425

    CrossRef

  11. 11
    S.A. Hurvitz, P.F. Peddi, Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer, Breast Diseases: A Year Book Quarterly, 2013, 24, 1, 79

    CrossRef

  12. 12
    John FR Robertson, Jean-Marc Ferrero, Hugues Bourgeois, Hagen Kennecke, Richard H de Boer, William Jacot, Jesse McGreivy, Samuel Suzuki, Min Zhu, Ian McCaffery, Elwyn Loh, Jennifer L Gansert, Peter A Kaufman, Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial, The Lancet Oncology, 2013, 14, 3, 228

    CrossRef

  13. 13
    Zhiqiang Mo, Manran Liu, Fangfang Yang, Haojun Luo, Zhenhua Li, Gang Tu, Guanglun Yang, GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer, Breast Cancer Research, 2013, 15, 6, R114

    CrossRef

  14. 14
    Laura W Bowers, David A Cavazos, Ilane XF Maximo, Andrew J Brenner, Stephen D Hursting, Linda A deGraffenried, Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression, Breast Cancer Research, 2013, 15, 4, R59

    CrossRef

  15. 15
    Michael Gnant, The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer, Current Oncology Reports, 2013, 15, 1, 14

    CrossRef

  16. 16
    Carlos H Barrios, André P Fay, Marcio Debiasi, Gustavo Werutsky, Endocrine resistance in advanced breast cancer: current evidence and future directions, Breast Cancer Management, 2012, 1, 4, 305

    CrossRef

  17. 17
    Lu Gan, Jian He, Xia Zhang, Yong-Jie Zhang, Guan-Zhen Yu, Ying Chen, Jun Pan, Jie-Jun Wang, Xi Wang, Expression profile and prognostic role of sex hormone receptors in gastric cancer, BMC Cancer, 2012, 12, 1, 566

    CrossRef

  18. 18
    Rocío García-Becerra, Nancy Santos, Lorenza Díaz, Javier Camacho, Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance, International Journal of Molecular Sciences, 2012, 14, 1, 108

    CrossRef

  19. 19
    Tae-Jung Kim, Ahwon Lee, Yeong-Jin Choi, Byung Joo Song, Hyeon Woo Yim, Chang Suk Kang, Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine Therapy, Journal of Breast Cancer, 2012, 15, 1, 79

    CrossRef

  20. 20
    W Ketchart, N Ogba, A Kresak, J M Albert, J J Pink, M M Montano, HEXIM1 is a critical determinant of the response to tamoxifen, Oncogene, 2011, 30, 33, 3563

    CrossRef

  21. 21
    C G Roberts, E K A Millar, S A O'Toole, C M McNeil, G M Lehrbach, M Pinese, P Tobelmann, R A McCloy, E A Musgrove, R L Sutherland, A J Butt, Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer, Oncogene, 2011, 30, 28, 3186

    CrossRef

  22. 22
    William R Miller, Markers of sensitivity, dependence and resistance to endocrine therapy for breast cancer, Expert Review of Endocrinology & Metabolism, 2011, 6, 3, 345

    CrossRef

  23. 23
    Richa Tiwary, Weiping Yu, Linda A deGraffenried, Bob G Sanders, Kimberly Kline, Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer, Breast Cancer Research, 2011, 13, 6, R120

    CrossRef

  24. 24
    Adam M. Brufsky, Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal women, Community Oncology, 2011, 8, 8, 343

    CrossRef

  25. 25
    H. Irene Su, Mary D. Sammel, Jamie Green, Luke Velders, Corrie Stankiewicz, Jennifer Matro, Ellen W. Freeman, Clarisa R. Gracia, Angela DeMichele, Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors, Cancer, 2010, 116, 3, 592

    CrossRef

  26. 26
    Anna-Karin Falck, Mårten Fernö, Pär-Ola Bendahl, Lisa Rydén, Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?, World Journal of Surgery, 2010, 34, 7, 1434

    CrossRef

  27. 27
    K Ueyama, K Ikeda, W Sato, N Nakasato, K Horie-Inoue, S Takeda, S Inoue, Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth, Cancer Gene Therapy, 2010, 17, 9, 624

    CrossRef

  28. 28
    Laura Muñoz, Magali Espinosa, Valeria Quintanar-Jurado, Alfredo Hidalgo, Jorge Melendez-Zajgla, Vilma Maldonado, Paradoxial changes in the expression of estrogen receptor alpha in breast cancer multicellular spheroids, Tissue and Cell, 2010, 42, 5, 334

    CrossRef

  29. 29
    Nitzan Levy, Sreenivasan Paruthiyil, Xiaoyue Zhao, Omar I. Vivar, Elise F. Saunier, Chandi Griffin, Mary Tagliaferri, Isaac Cohen, Terence P. Speed, Dale C. Leitman, Unliganded estrogen receptor-β regulation of genes is inhibited by tamoxifen, Molecular and Cellular Endocrinology, 2010, 315, 1-2, 201

    CrossRef

  30. 30
    Tristin Abair, Paul Card, Joyce O'Shaughnessy, Highlights from: The 2008 San Antonio Breast Cancer Symposium December 10–14, 2008 San Antonio, TX, Clinical Breast Cancer, 2009, 9, 1, 8

    CrossRef

  31. 31
    Sara A Hurvitz, Richard S Finn, What’s positive about ‘triple-negative’ breast cancer?, Future Oncology, 2009, 5, 7, 1015

    CrossRef